These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21517255)

  • 1. Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy.
    Hassan BA; Yusoff ZB
    Asian Pac J Cancer Prev; 2011; 12(1):185-91. PubMed ID: 21517255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race.
    Hassan BA; Yusoff ZB
    Asian Pac J Cancer Prev; 2010; 11(6):1523-7. PubMed ID: 21338191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
    Yarker YE; McTavish D
    Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prophylaxis of chemotherapy-induced vomiting and nausea].
    Tóth J; Szántó J
    Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Single-dose First-generation 5-HT
    Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
    Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron: an update on its clinical use in the management of nausea and vomiting.
    Aapro M
    Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
    Eliasen A; Dalhoff K; Mathiasen R; Schmiegelow K; Rechnitzer C; Schelde AB; Perwitasari DA; Tsuji D; Brok J
    Crit Rev Oncol Hematol; 2020 May; 149():102939. PubMed ID: 32259776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
    Hsu YC; Chen CY; Tam KW; Hsu CY
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1597-1609. PubMed ID: 33993343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.
    Sigsgaard T; Herrstedt J; Christensen P; Andersen O; Dombernowsky P
    Support Care Cancer; 2000 May; 8(3):233-7. PubMed ID: 10789966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
    Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
    Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
    Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
    Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State of the Art Antiemetic Therapy for Cancer Patients.
    Lau TK; Yip CH; Yeo W
    Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of aprepitant for CHOP chemotherapy-induced nausea, vomiting, and anorexia.
    Morita M; Kishi S; Ookura M; Matsuda Y; Tai K; Yamauchi T; Ueda T
    Curr Probl Cancer; 2017; 41(6):419-425. PubMed ID: 29061362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.